Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
NCT07634536Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Nov 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in acute myeloid leukemia (AML), Myeloproliferative Neoplasm (MPN) and myelodysplastic syndrome (MDS) (2 cohorts), sponsored by Stanford University. Primary endpoints: Non-Relapse Mortality at Day 100 and Neutrophil Engraftment at Day 100. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
acute myeloid leukemia (AML)Myeloproliferative Neoplasm (MPN)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07634536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634536.